Clinica Chimica Acta最新文献

{"title":"IL-25 expression in induced sputum may serve as a reliable biomarker in children with bronchial asthma","authors":"Yun Zhang ,&nbsp;Yuna Chang ,&nbsp;Lu Cheng,&nbsp;Jing Wang,&nbsp;Xiaoling Wei,&nbsp;Min Xue","doi":"10.1016/j.cca.2025.120366","DOIUrl":"10.1016/j.cca.2025.120366","url":null,"abstract":"<div><h3>Background</h3><div>Asthma is a chronic respiratory disease characterized by reversible airway obstruction and persistent airway inflammation, presenting as a highly heterogeneous disorder in children. Further understanding of its complexity is essential to identify applicable biomarkers and targeted therapies. Interleukin-25 (IL-25) has been shown to play a critical role in the pathogenesis of asthma.</div></div><div><h3>Methods</h3><div>To investigate the association between IL and 25 expression and clinical characteristics, we enrolled<!--> <!-->46 children with asthma (age 6–17 years)<!--> <!-->and<!--> <!-->15 age-matched healthy controls. Asthma patients were stratified into<!--> <!-->Group A (untreated, n = 24)<!--> <!-->and<!--> <!-->Group B (treatment-controlled, n = 22). IL-25 protein levels in serum and IL-25 mRNA in induced sputum were quantified using<!--> <!-->ELISA and PCR, respectively.</div></div><div><h3>Results</h3><div>No significant intergroup differences existed in age (P = 0.32), sex (P = 0.67), or BMI (P = 0.144).<!--> <!-->IL-25 mRNA in sputum<!--> <!-->was significantly elevated in both groups versus controls (P &lt; 0.001 in Group A and P &lt; 0.05 in Group B).<!--> <!-->Sputum IL-25 protein levels<!--> <!-->were<!--> <!-->higher in Group A versus controls (P &lt; 0.001) and Group B (P &lt; 0.05). IL-25 mRNA expression in sputum<!--> <!-->was significantly higher in Group A (without anti-asthma drugs) compared to Group B (with controlled asthma treated with anti-asthma drugs) (P &lt; 0.05 in both induced sputum and blood). Furthermore, IL-25 mRNA expression correlated with CRP (P = 0.007), FeNO (P = 0.04), FEV₁/FVC (%) (P = 0.01), induced sputum eosinophil count (%) (P = 0.03), disease severity (P = 0.042), and anti-asthma treatment (P &lt; 0.05). Notably, IL-25 levels in induced sputum decreased significantly at both molecular and gene levels following anti-asthma treatment, suggesting its potential as a biomarker for evaluating treatment efficacy and asthma control.</div></div><div><h3>Conclusion</h3><div>IL-25 expression in induced sputum may serve as a reliable biomarker in children with bronchial asthma, though further large-scale studies are needed to confirm these findings.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"575 ","pages":"Article 120366"},"PeriodicalIF":3.2,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144105492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic pathway alterations in cerebrospinal fluid as diagnostic biomarkers for primary central nervous system lymphoma","authors":"Jingjing Ma ,&nbsp;Di Wang ,&nbsp;Xiangyu Li ,&nbsp;Yaqi Zhang ,&nbsp;Qiming Tang ,&nbsp;Yun Ding ,&nbsp;Xiao Li ,&nbsp;Bo Jin ,&nbsp;Ruben Y. Luo ,&nbsp;Sheeno Thyparambil ,&nbsp;Zhi Han ,&nbsp;C.James Chou ,&nbsp;Ashlee Zhou ,&nbsp;James Schilling ,&nbsp;Zhiguang Lin ,&nbsp;Yan Ma ,&nbsp;Qing Li ,&nbsp;Mengxue Zhang ,&nbsp;Karl G. Sylvester ,&nbsp;Seema Nagpal ,&nbsp;Bobin Chen","doi":"10.1016/j.cca.2025.120377","DOIUrl":"10.1016/j.cca.2025.120377","url":null,"abstract":"<div><div>Primary Central Nervous System Lymphoma (PCNSL) is a rare and aggressive type of hematological malignancy that can pose diagnostic challenges. Early detection is critical for effective treatment and better patient outcomes. The goal of this study was to assess the potential of metabolic pathway alterations as diagnostic and differential biomarker. We conducted a metabolomics analysis from GEO transcriptomic datasets on brain/lymph nodes. Enriched and significant pathways were validated from patient’s CSF samples from PCNSL, metastatic cancers and non-malignant controls, with mass spectrometry. Next, we utilized machine learning models to assess the separation performance of PCNSLs from other patients and develop diagnostic and differential diagnosis panels. Key metabolic pathways were discovered from GEO datasets analysis and significantly enriched in the CSF of PCNSL. Porphyrin metabolism and fatty acid-related pathways were significantly enriched from diagnostic panel and AUC was 0.88. Additionally, aminoacyl-tRNA biosynthesis, glutathione metabolism, and several amino acid pathways were significantly enriched from differential panel and the AUC was 0.95. Our study highlights the diagnostic biomarker potential of metabolic pathway alterations in CSF for PCNSL, which could lead to the development of non-invasive and reliable diagnostic tool for PCNSL.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"575 ","pages":"Article 120377"},"PeriodicalIF":3.2,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144105494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of a panel of lncRNAs derived from urinary extracellular vesicles as non-invasive diagnostic biomarkers for bladder cancer","authors":"Chen Chen ,&nbsp;Ying Wu ,&nbsp;Junlu Wu,&nbsp;Ruixin Sun,&nbsp;Yaran Li,&nbsp;Yiwen Yao,&nbsp;Dong Li","doi":"10.1016/j.cca.2025.120376","DOIUrl":"10.1016/j.cca.2025.120376","url":null,"abstract":"<div><div>Bladder cancer (BLCA) is a common malignant tumor of the urinary system and is histopathologically divided into high-grade and low-grade BLCA. Accurate diagnosis of BLCA and high-grade BLCA are critical for clinical treatment and early intervention. High-throughput RNA-seq was performed to explore dysregulated long non-coding RNAs (lncRNAs) in urinary extracellular vesicles (uEVs) from BLCA patients, and their expression levels<!--> <!-->were<!--> <!-->examined in<!--> <!-->a<!--> <!-->large cohort of uEVs samples using qRT-PCR. We<!--> <!-->examined<!--> <!-->the expression<!--> <!-->levels and subcellular localization of the lncRNAs in BLCA tissues and<!--> <!-->cell<!--> <!-->lines. We analyzed the correlation between the expression levels of lncRNAs in uEVs and clinical parameters and assessed their clinical value as diagnostic biomarkers for BLCA and high-grade BLCA using receiver operating characteristic (ROC) curve. Through high-throughput RNA-seq, we identified several dysregulated lncRNAs (MALAT1, SCARNA10, LINC00963 and LINC01578) in uEVs from BLCA patients. The lncRNAs were significantly upregulated in uEVs of BLCA patients, however with varying expression levels in tissues and cell lines. The lncRNAs<!--> <!-->are<!--> <!-->predominantly<!--> <!-->localized<!--> <!-->in<!--> <!-->the nucleus of BLCA cell lines. Elevated expression levels of the lncRNAs were associated with adverse factors, including higher tumor grade and larger tumor diameter. ROC<!--> <!-->curve analysis showed that<!--> <!-->the combination of four lncRNAs in uEVs and the existing marker nuclear matrix protein 22 provided substantial diagnostic value for BLCA and high-grade BLCA, with area under curve values of 0.900 and 0.917, respectively. The lncRNA panel derived from uEVs may serve as a promising non-invasive biomarker for diagnosing BLCA and high-grade BLCA.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"575 ","pages":"Article 120376"},"PeriodicalIF":3.2,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sclerostin in ankylosing spondylitis: A meta-analysis","authors":"Li-Wei Jiang ,&nbsp;Mei-Ling Yuan ,&nbsp;Li-Na Jiang ,&nbsp;Ai-Xin Xia ,&nbsp;Jia-Qing Chen ,&nbsp;Yan-Ping Li ,&nbsp;Cheng-Gui Miao ,&nbsp;Yan-Mei Mao","doi":"10.1016/j.cca.2025.120375","DOIUrl":"10.1016/j.cca.2025.120375","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to assess circulating sclerostin levels in patients with ankylosing spondylitis (AS).</div></div><div><h3>Methods</h3><div>The databases of PubMed, Embase, Medline, Web of Science, The Cochrane Library, China National Knowledge Infrastructure Database (CNKI), China Biomedical Literature Database (CBM), Wanfang Med Online Database (Wanfang), China Science and Technology Journal Database (VIP) were used to collect all relevant published articles (up to 26 August 2024). The pooled standardized mean difference (<em>SMD</em>) with 95% confidence interval (CI) was calculated by the random-effect model.</div></div><div><h3>Results</h3><div>A total of 22 studies were included, including 1354 AS patients and 871 normal controls. There was no significant difference in the circulating sclerostin levels between AS patients and normal controls (<em>SMD</em> = −0.03, 95%CI = −0.51 to 0.46, <em>P</em> = 0.92). Subgroup analysis showed that the South America group, the Africa group, cohort study group, bath ankylosing spondylitis disease activity index (BASDAI) score &lt; 4 group, bath ankylosing spondylitis functional index (BASFI) score &lt; 4 group, C-reactive protein (CRP) ≤ 10 mg/L group, modified stoke ankylosing spondylitis spinal score (mSASSS) ≥ 30 group, TECO medical group and other enzyme-linked immunosorbent assay (ELISA) kits group had lower levels of the circulating sclerostin. Egger’s linear regression test indicated that there was no significant publication bias. Sensitivity analysis showed that the results were stable.</div></div><div><h3>Conclusion</h3><div>There was no significant difference in circulating sclerostin levels between AS patients and normal controls. However, the circulating sclerostin levels in AS patients were influenced by region, type of study, BASDAI score, BASFI score, CRP, mSASSS, and ELISA kits. Therefore, it may serve as an indicator to evaluate disease activity, functional status, inflammation and imaging progression in AS patients.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"575 ","pages":"Article 120375"},"PeriodicalIF":3.2,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"End-tidal carbon monoxide levels as a point-of-care biomarker for the early detection of hemolytic disease in Chinese neonates","authors":"Ge Yang ,&nbsp;Kun Zhang ,&nbsp;Li Deng ,&nbsp;Huijuan Liu ,&nbsp;Xinrui Fu ,&nbsp;Yue Hu ,&nbsp;Xiaodan Yan ,&nbsp;Xiaoyun Zhou ,&nbsp;Wei Luo ,&nbsp;Siyao Wang ,&nbsp;Xiaotong Ye ,&nbsp;Tianlang Zhang ,&nbsp;Fan Li ,&nbsp;Zhuanxia Huo ,&nbsp;Yan Jiang ,&nbsp;Shan Zeng ,&nbsp;Dehua Wu ,&nbsp;Yuan Yuan ,&nbsp;Huayan Zhang","doi":"10.1016/j.cca.2025.120368","DOIUrl":"10.1016/j.cca.2025.120368","url":null,"abstract":"<div><h3>Objective</h3><div>Hemolytic disease of newborn (HDN) is a leading risk factor for severe neonatal hyperbilirubinemia. While end-tidal carbon monoxide (CO) corrected for ambient CO (ETCOc) reflects the endogenous rate of bilirubin production, there remain translational gaps in understanding the link between ETCOc and HDN. We aimed to evaluate ETCOc levels as an indicator of increased bilirubin production in HDN.</div></div><div><h3>Methods</h3><div>This secondary analysis of the HEME (Hyperbilirubinemia risk Evaluation and Management by ETCOc) trial included near-term/term neonates (≥35 weeks’ gestation, birth weight ≥ 2000 g) with transcutaneous bilirubin (TcB) levels &gt; 40th percentile within 72 h of birth. Infants diagnosed with HDN, defined as the presence of ABO HDN and/or glucose-6-phosphate dehydrogenase (G6PD) deficiency, were compared with those without HDN. ETCOc was measured within the first 7 days of life (DOL).</div></div><div><h3>Results</h3><div>Of 2500 infants studied, 171 (6.8%) were diagnosed with HDN. ETCOc levels within 72 h of birth were significantly higher in HDN cases compared with controls. ETCOc percentiles within 7 DOL showed trends with fluctuations. Each 1 ppm incremental increase in ETCOc was each significantly associated with odds ratios of 3.90 (95 %CI 2.89–5.29), 2.72 (95 %CI 1.89–3.92), and 2.47 (95 %CI 1.21–5.02) of developing HDN early after life (<span><math><mo>≤</mo></math></span> 72 h).</div></div><div><h3>Conclusion</h3><div>Early postnatal ETCOc was strongly associated with increased risk of HDN in newborns of Southern China. Our findings highlight the potential of ETCOc as a noninvasive point of care biomarker for early hemolysis identification. Integration of ETCOc measurements into existing screening protocols could refine risk stratification and guide timely interventions, particularly in regions with a high prevalence of HDN.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"575 ","pages":"Article 120368"},"PeriodicalIF":3.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144084415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early diagnosis of the Need for surgical drainage in chronic pancreatitis patients based on serum metabolomics","authors":"Xu Xu ,&nbsp;Sixiang Liu ,&nbsp;Min Shao ,&nbsp;Ling Wu ,&nbsp;Qianhui Ouyang ,&nbsp;Qi Yi ,&nbsp;Ying Huang ,&nbsp;Jia Wang ,&nbsp;Chaochao Tan","doi":"10.1016/j.cca.2025.120369","DOIUrl":"10.1016/j.cca.2025.120369","url":null,"abstract":"<div><h3>Purpose</h3><div>Chronic pancreatitis (CP) is a chronic inflammatory disease caused by multiple factors. Numerous studies have found that implementing surgical drainage in the early stages of CP can help alleviate pain and improve prognosis in patients. However, there is currently no consensus on clinical indications for surgical drainage in the early stages of CP, making it difficult to determine whether surgical drainage is necessary. This study aims to use metabolomics methods to identify potential biomarkers that can differentiate whether CP patients require surgical drainage.</div></div><div><h3>Methods</h3><div>This study included two cohorts. The training cohort consisted of 32 serum samples from CP patients and 31 serum samples from healthy controls. The validation cohort comprised 73 serum samples from CP patients and 27 serum samples from healthy controls. All serum samples from CP patients were collected within 24 h of hospital admission. Liquid chromatography-tandem mass spectrometry (LC-MS) was used to perform metabolomic analysis on all collected serum samples.</div></div><div><h3>Results</h3><div>Based on the validation cohort, 24 differential metabolites, including 1-(6-[3]-ladderane-hexanyl)-2-(8-[3]-ladderane-octanyl)-<em>sn</em>-glycerophosphocholine, PE(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)), and PGP(16:0/20:4(5Z,8Z,11Z,14Z)), were identified as potential biomarkers for distinguishing whether CP patients require surgical drainage. Among these, the combination of 1-(6-[3]-ladderane-hexanyl)-2-(8-[3]-ladderane-octanyl)-<em>sn</em>-glycerophosphocholine and PE(18:1(9Z)/20:4(5Z,8Z,11Z,14Z)) demonstrated improved diagnostic value in joint ROC analysis, with an AUC value of 0.819 (95% CI: 0.691–0.924).</div></div><div><h3>Conclusion</h3><div>This study represents the first prospective cohort research to identify 24 differential metabolites in serum through metabolomic profiling, which can be used for the early diagnosis of whether CP patients require surgical drainage.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120369"},"PeriodicalIF":3.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A proof-of-concept practical approach for achieving equivalent results from non-harmonized measurement methods while awaiting harmonization: The CA 125 example","authors":"Hikmet Can Çubukçu ,&nbsp;Oğuzhan Zengi ,&nbsp;Hamit Hakan Alp ,&nbsp;Murat Cihan ,&nbsp;Kamil Taha Uçar ,&nbsp;Marc Thelen ,&nbsp;Mauro Panteghini","doi":"10.1016/j.cca.2025.120355","DOIUrl":"10.1016/j.cca.2025.120355","url":null,"abstract":"<div><h3>Background</h3><div>Laboratory test results are crucial for clinical decisions, yet inconsistencies arise when measurements are not harmonized due to the lack of suitable higher-order references. This study introduces an approach to improve result comparability across different measurement systems, applicable until full metrological harmonization of the measurand is achieved.</div></div><div><h3>Methods</h3><div>A linear transformation formula was developed, utilizing the 2.5th and 97.5th percentiles of data from source and target methods, to adjust source method results. The feasibility of this formula was tested using carbohydrate antigen 125 (CA 125) data from two commercial assays provided by Roche Diagnostics and Abbott Diagnostics. Method comparison statistics, including difference plots and Passing-Bablok regression, were used to evaluate the transformation’s effectiveness before and after adjustment. A web application, “Result Transformer,” was developed to facilitate the application of the transformation process.</div></div><div><h3>Results</h3><div>Prior to transformation, the median relative difference between the Roche and Abbott CA 125 assays was 37.7% (95% CI: 34.5–40.8%), exceeding acceptable bias. Passing-Bablok regression yielded a slope of 1.450 (95% CI: 1.400–1.485) and an intercept of −0.83 kU/L (95% CI: −1.50 to −0.29). After adjustment using the proposed approach, the median relative difference decreased to 6.0% (95% CI: 4.3–7.7%), falling within the desirable acceptable bias goal. The slope and intercept of the regression equation improved to 1.075 (95% CI: 1.039–1.102) and −0.12 kU/L (95% CI: −0.71 to 0.19), respectively.</div></div><div><h3>Conclusion</h3><div>The proposed transformation method effectively improved the comparability of results from different assays, permitting a more consistent test result interpretation during patient follow-up.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"575 ","pages":"Article 120355"},"PeriodicalIF":3.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144072243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a machine learning model based on complete blood counts to predict clinical outcomes in urothelial carcinoma patients","authors":"Jie Cheng ,&nbsp;Fei Chen ,&nbsp;Yunxiao Song ,&nbsp;Siyang Wang ,&nbsp;Jingying Jia ,&nbsp;Hang Wang ,&nbsp;Houbao Liu","doi":"10.1016/j.cca.2025.120367","DOIUrl":"10.1016/j.cca.2025.120367","url":null,"abstract":"<div><div>Urothelial carcinoma (UC) is a highly malignant disease with significant public health implications. Despite advancements in oncology, early diagnosis and effective prognostic tools remain limited. This study aimed to develop a machine learning model using complete blood count (CBC) data to predict clinical outcomes in UC patients. A retrospective, two-center cohort study was conducted, analyzing 23 CBC variables from 477 UC patients at Xuhui Hospital of Fudan University (discovery cohort) and 297 UC patients from Putuo People’s Hospital of Tongji University (validation cohort). CBC data were collected before treatment and three months posttreatment, with overall survival (OS) as the primary endpoint. Nine machine learning models were developed in the discovery cohort and validated independently. Feature selection identified a logistic regression (LR) model incorporating white blood cell (WBC) count and lymphocyte percentage (LYMPH%) as the optimal predictor. The model achieved high performance, with an area under the ROC curve (AUC) of 0.93 (95 %CI: 0.90–0.97), area under the precision-recall curve (AUPRC) of 0.94 (95 %CI: 0.89–0.99), positive predictive value (PPV) of 0.87 (95 %CI: 0.75–0.98), negative predictive value (NPV) of 0.82 (95 %CI: 0.78–0.87), accuracy of 0.83 (95 %CI: 0.80–0.88), and F1 score of 0.82 (95 %CI: 0.79–0.86) in the discovery cohort, and comparable results in the validation cohort (AUC 0.88 [95 %CI: 0.84–0.93], AUPRC 0.81 [95 %CI: 0.75–0.86], PPV 0.77 [95 %CI: 0.71–0.84], NPV 0.89 [95 %CI: 0.84–0.95], accuracy 0.84 [95 %CI: 0.80–0.89], and F1 score 0.80 [95 %CI: 0.74–0.87]). Decision curve analysis demonstrated consistent net benefits, while Kaplan–Meier analysis indicated significantly shorter OS in the “predict worse outcomes” subgroup. Posttreatment, WBC counts increased and LYMPH% decreased in deceased patients, whereas survivors showed the opposite trends (P &lt; 0.05). These findings suggest that a simple, cost-effective CBC-based machine learning model can effectively predict UC prognosis, aiding clinical decision-making.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"575 ","pages":"Article 120367"},"PeriodicalIF":3.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuous glucose monitoring: Minimally and non-invasive technologies","authors":"Jeong Eun Lee ,&nbsp;Badrinathan Sridharan ,&nbsp;Daehun Kim ,&nbsp;Yeongho Sung ,&nbsp;Jin Hyeong Park ,&nbsp;Hae Gyun Lim","doi":"10.1016/j.cca.2025.120358","DOIUrl":"10.1016/j.cca.2025.120358","url":null,"abstract":"<div><div>This paper highlights technological advancements in non-invasive blood glucose monitoring against the backdrop of increasing global prevalence of diabetes. Traditional monitoring methods, primarily invasive methods face limitations in providing continuous glucose level data, which is essential for effective and timely diagnosis of disease stage and for determining the optimal therapeutic strategy. Recent non-invasive technologies encompass optical, acoustic, electromagnetic, and chemical approaches. These technologies exploit the intrinsic properties of glucose, such as its optical absorption coefficients, to offer promising avenues for less intrusive blood glucose monitoring. Despite these advancements, challenges in achieving high accuracy persist due to interference from substances like water and other blood components. This underlines the need for sophisticated algorithms and sensor designs for accurate glucose estimation. Further research is required to integrate various sensing techniques and advanced data processing to enhance accuracy and user-friendliness. In conclusion, while significant progress has been made, developing a reliable, convenient, and accessible method for non-invasive glucose monitoring is crucial for transforming diabetes management and improving patients’ quality of life.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"575 ","pages":"Article 120358"},"PeriodicalIF":3.2,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144084413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma protein biomarkers for long COVID-19: Predictors of symptom severity and mortality risk","authors":"Kaleem Maqsood ,&nbsp;Shaaf Ahmad ,&nbsp;Azeem Saeed ,&nbsp;Nabila Roohi","doi":"10.1016/j.cca.2025.120350","DOIUrl":"10.1016/j.cca.2025.120350","url":null,"abstract":"<div><h3>Introduction</h3><div>Long COVID-19 is marked by persistent symptoms beyond the acute phase, necessitating a deeper understanding of mortality risk factors for effective management. Plasma proteins hold promise as prognostic markers, offering insights into disease progression and aiding in mortality risk assessment.</div></div><div><h3>Method</h3><div>A total of 240 patients and 89 healthy controls were enrolled for this study. Two months post-COVID follow-up, patients were categorized as survivors (n = 212) and non-survivors (n = 28). Plasma samples underwent 2-dimensional Gel Electrophoresis (2DE) for protein separation, followed by LC-MS/MS for protein identification, and validation was performed using ELISA. Proteomic data analysis was conducted using Mascot version 2.3.02 and Samespots software 4.5.1. Statistical analyses were carried out using GraphPad Prism and IBM SPSS.</div></div><div><h3>Results</h3><div>LC-MS/MS identified fibrinogen (Spot 14; 52.15 kDa/5.32 pI; protein score 2293) and haptoglobin (Spot 08; 45.86 kDa/6.56 pI; protein score 453) as prospective predictive biomarkers. ELISA results confirmed increased plasma levels of fibrinogen and haptoglobin in severe cases (P &lt; 0.001 for both) and non-survivors (P &lt; 0.01 and P &lt; 0.0086, respectively). ROC analysis showed haptoglobin had moderate predictive power for mortality (AUC = 0.68; P = 0.0025), surpassing fibrinogen (AUC = 0.62; P = 0.0374).</div></div><div><h3>Conclusion</h3><div>Plasma fibrinogen and haptoglobin are promising biomarkers for assessing disease severity and mortality risk in long COVID. These findings highlight their potential for prognostic applications, warranting further research into their mechanistic roles in COVID-19 and broader clinical implications.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"575 ","pages":"Article 120350"},"PeriodicalIF":3.2,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144071008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}